Literature DB >> 29782348

Renal Ewing sarcoma treated with apatinib.

Yang Zhao1, Ye Chen1, Ke Cheng1, Zhi-Ping Li1, Hao Zeng2, Ji-Yan Liu1.   

Abstract

Renal Ewing sarcoma (RES) is an extremely rare disease. The standard treatment for this disease is lacking, and clinical experience needs to be accumulated. Here, we report a case of RES that rapidly developed to metastatic disease and was refractory to radiotherapy and chemotherapy; however, the case obtained a partial response based on Choi criteria by orally taking antiangiogenic drug apatinib. Our case suggests that apatinib may be a therapeutic option for RES.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29782348     DOI: 10.1097/CAD.0000000000000630

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  2 in total

1.  A rare entity of Primary Ewing sarcoma in kidney.

Authors:  Li Cheng; Yujie Xu; Hong Song; Houbao Huang; Dong Zhuo
Journal:  BMC Surg       Date:  2020-11-11       Impact factor: 2.102

2.  Quality of life and Q-TWiST were not adversely affected in Ewing sarcoma patients treated with combined anlotinib, irinotecan, and vincristine: (Peking University People's Hospital Ewing sarcoma trial-02, PKUPH-EWS-02).

Authors:  Sen Dong; Kunkun Sun; Lu Xie; Jie Xu; Xin Sun; Tingting Ren; Yi Huang; Rongli Yang; Xiaodong Tang; Fan Yang; Jin Gu; Wei Guo
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.